Cytokinfrigivelsessyndrom ved behandling af kræftsygdom med CAR-T og T-celleengagere

Bue Ross Agner; Caroline Hasselbalch Riley; Søren Lykke Petersen; Iben Spanggaard; Martin Hutchings; Kristoffer Staal Rohrberg; Martin Højgaard

doi:10.61409/V08230544

Cytokinfrigivelsessyndrom ved behandling af kræftsygdom med CAR-T og T-celleengagere

Bue Ross Agner, Caroline Hasselbalch Riley, Søren Lykke Petersen, Iben Spanggaard, Martin Hutchings, Kristoffer Staal Rohrberg, Martin Højgaard^*

^*Corresponding author af dette arbejde

Abstract

T-cell-based immunotherapy has recently evolved as a treatment option for a number of haematological malignancies and is also being developed in solid tumours. A common side effect of chimeric antigen T-cell therapy (CAR-T) and treatment with T-cell engagers is cytokine release syndrome (CRS), which is a potentially life-threatening condition characterized by release of inflammatory mediators. The treatment of CRS is similar to that of other hyper-inflammatory conditions and involves supportive treatment as well as immunosuppressive therapy. The risk of CRS can be mitigated by step-up dosing and immunosuppressive pre-treatment, as argued in this review.

Bidragets oversatte titel	Cytokine release syndrome caused by antineoplastic treatment with CAR-T and T-cell engaging therapies
Originalsprog	Dansk
Artikelnummer	V08230544
Tidsskrift	Ugeskrift for Laeger
Vol/bind	186
Udgave nummer	9
ISSN	0041-5782
DOI	https://doi.org/10.61409/V08230544
Status	Udgivet - 26 feb. 2024

Emneord

Humans
Receptors, Chimeric Antigen
Cytokine Release Syndrome
Antineoplastic Agents
Immunotherapy
Immunosuppressive Agents/adverse effects

Adgang til dokumentet

10.61409/V08230544

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{a831d6590d414a8c8158db855c75c9b6,

title = "Cytokinfrigivelsessyndrom ved behandling af kr{\ae}ftsygdom med CAR-T og T-celleengagere",

abstract = "T-cell-based immunotherapy has recently evolved as a treatment option for a number of haematological malignancies and is also being developed in solid tumours. A common side effect of chimeric antigen T-cell therapy (CAR-T) and treatment with T-cell engagers is cytokine release syndrome (CRS), which is a potentially life-threatening condition characterized by release of inflammatory mediators. The treatment of CRS is similar to that of other hyper-inflammatory conditions and involves supportive treatment as well as immunosuppressive therapy. The risk of CRS can be mitigated by step-up dosing and immunosuppressive pre-treatment, as argued in this review.",

keywords = "Humans, Receptors, Chimeric Antigen, Cytokine Release Syndrome, Antineoplastic Agents, Immunotherapy, Immunosuppressive Agents/adverse effects",

author = "Agner, {Bue Ross} and Riley, {Caroline Hasselbalch} and Petersen, {S{\o}ren Lykke} and Iben Spanggaard and Martin Hutchings and Rohrberg, {Kristoffer Staal} and Martin H{\o}jgaard",

note = "Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/. Fase1Rigshospitalet",

year = "2024",

month = feb,

day = "26",

doi = "10.61409/V08230544",

language = "Dansk",

volume = "186",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "9",

}

TY - JOUR

T1 - Cytokinfrigivelsessyndrom ved behandling af kræftsygdom med CAR-T og T-celleengagere

AU - Agner, Bue Ross

AU - Riley, Caroline Hasselbalch

AU - Petersen, Søren Lykke

AU - Spanggaard, Iben

AU - Hutchings, Martin

AU - Rohrberg, Kristoffer Staal

AU - Højgaard, Martin

N1 - Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/. Fase1Rigshospitalet

PY - 2024/2/26

Y1 - 2024/2/26

N2 - T-cell-based immunotherapy has recently evolved as a treatment option for a number of haematological malignancies and is also being developed in solid tumours. A common side effect of chimeric antigen T-cell therapy (CAR-T) and treatment with T-cell engagers is cytokine release syndrome (CRS), which is a potentially life-threatening condition characterized by release of inflammatory mediators. The treatment of CRS is similar to that of other hyper-inflammatory conditions and involves supportive treatment as well as immunosuppressive therapy. The risk of CRS can be mitigated by step-up dosing and immunosuppressive pre-treatment, as argued in this review.

AB - T-cell-based immunotherapy has recently evolved as a treatment option for a number of haematological malignancies and is also being developed in solid tumours. A common side effect of chimeric antigen T-cell therapy (CAR-T) and treatment with T-cell engagers is cytokine release syndrome (CRS), which is a potentially life-threatening condition characterized by release of inflammatory mediators. The treatment of CRS is similar to that of other hyper-inflammatory conditions and involves supportive treatment as well as immunosuppressive therapy. The risk of CRS can be mitigated by step-up dosing and immunosuppressive pre-treatment, as argued in this review.

KW - Humans

KW - Receptors, Chimeric Antigen

KW - Cytokine Release Syndrome

KW - Antineoplastic Agents

KW - Immunotherapy

KW - Immunosuppressive Agents/adverse effects

UR - http://www.scopus.com/inward/record.url?scp=85187201736&partnerID=8YFLogxK

U2 - 10.61409/V08230544

DO - 10.61409/V08230544

M3 - Review

C2 - 38445322

SN - 0041-5782

VL - 186

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 9

M1 - V08230544

ER -

Cytokinfrigivelsessyndrom ved behandling af kræftsygdom med CAR-T og T-celleengagere

Abstract

Emneord

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater